Analystscheered a draft statement from the Centers for Medicare and Medicaid Services (CMS) that said the government plans to pay for prostate cancer treatment Provenge, made by Seattle-based biotechnology firm Dendreon.
The stock is also being cheered on by stock analysts and newsletter writers (see box, opposite), who are brushing aside the self-dealing through which Friedland has increased his stake.
The stock is also being cheered on by stock analysts and newsletter writers (see box, p. 132), who are brushing aside the self-dealing through which Friedland has increased his stake.